Vimarsana
Biggest News Aggregation in the World

Symplicity Flex News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Symplicity Flex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Symplicity Flex Today - Breaking & Trending Today

Renal denervation lowers BP regardless of antihypertensive regimen, polypharmacy burden - Vimarsana News

Renal denervation lowers BP regardless of antihypertensive regimen, polypharmacy burden

Renal denervation lowered blood pressure out to 36 months, regardless of baseline antihypertensive class combinations and polypharmacy burden, according to an analysis of the Global SYMPLICITY Registry DEFINE.At 36 months, 31% of participants decreased the number of antihypertensive drug classes, according to the study published in Hypertension.

Source: healio.com
BP Reduction With Renal Denervation Still Evident a Decade On - Vimarsana News

BP Reduction With Renal Denervation Still Evident a Decade On

The new analysis has several limitations, but Deepak Bhatt says it provides reassurances about the durability of the procedure.

Source: tctmd.com
Legacy of Neutral SYMPLICITY HTN-3 Recast by Long-term Outcomes - Vimarsana News

Legacy of Neutral SYMPLICITY HTN-3 Recast by Long-term Outcomes

Although interest in renal denervation in hypertension fell off after disappointing results from the 2014 trial, a new, longer-term analysis argues the treatment may have 'worked' after all.

SYMPICITY HTN-3's Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss - Vimarsana News

SYMPICITY HTN-3's Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Experts grappled with how to understand the positive findings given that the trial missed its primary endpoint at 6 months.

Source: tctmd.com
SYMPLICITY HTN-3's Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss - Vimarsana News

SYMPLICITY HTN-3's Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Experts grappled with how to understand the positive findings given that the trial missed its primary endpoint at 6 months.

Source: tctmd.com